Related Experiment Video

Updated: Jul 4, 2026

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins
08:13

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins

Published on: November 30, 2021

PPARgamma Inhibitors as Novel Tubulin-Targeting Agents

Katherine L Schaefer1

  • 1Gastroenterology and Hepatology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.

PPAR Research
|May 30, 2008
PubMed

Insights

PPARgamma inhibitor T0070907 reduces tubulin levels and suppresses tumor growth, suggesting novel anti-cancer drug mechanisms beyond microtubule polymerization. This offers new therapeutic targets for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Microtubule-targeting agents (MTAs) are effective cancer drugs but face resistance.
  • Current MTAs disrupt microtubule polymerization and dynamics.
  • Novel mechanisms for anti-cancer drugs are needed to overcome resistance.

Purpose of the Study:

  • To review PPARgamma inhibitors' role in cancer cell death.
  • To emphasize the tubulin phenotype and PPAR-dependence in cancer therapy.
  • To identify potential novel mechanisms of action for anti-cancer drugs.

Main Methods:

  • Review of existing literature on PPARgamma inhibitors and cancer.
  • Analysis of studies investigating T0070907's effect on tubulin levels and tumor growth.
  • In vitro assessment of T0070907's impact on microtubule polymerization.

Main Results:

  • PPARgamma inhibitor T0070907 reduces tubulin levels in colorectal cancer cells.
  • T0070907 suppresses tumor growth in a murine xenograft model.
  • T0070907 does not affect microtubule polymerization in vitro.

Conclusions:

  • T0070907 suggests a novel mechanism of action for anti-cancer drugs.
  • This mechanism may not involve direct modulation of microtubule polymerization.
  • Exploitable cancer therapeutic targets beyond current MTA mechanisms may exist.

More Related Videos

Optimizing Tubulin Yield from Porcine Brain Tissue06:30

Optimizing Tubulin Yield from Porcine Brain Tissue

Published on: October 11, 2024

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...